Chemistry:Funapide
From HandWiki
Short description: Analgesic drug under development
 | |
| Clinical data | |
|---|---|
| Routes of administration | By mouth, topical |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C22H14F3NO5 |
| Molar mass | 429.351 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Funapide (INN) (former developmental code names TV-45070 and XEN402) is a novel analgesic under development by Xenon Pharmaceuticals (formerly in partnership with Teva Pharmaceutical Industries) for the treatment of a variety of chronic pain conditions, including osteoarthritis, neuropathic pain, postherpetic neuralgia, and erythromelalgia, as well as dental pain.[1][2][3][4] It acts as a small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker.[1][2][4] Funapide is being evaluated in humans in both oral and topical formulations, and as of July 2014, has reached phase IIb clinical trials.[1][3]
See also
References
- ↑ 1.0 1.1 1.2 "Recent progress in sodium channel modulators for pain". Bioorganic & Medicinal Chemistry Letters 24 (16): 3690–3699. August 2014. doi:10.1016/j.bmcl.2014.06.038. PMID 25060923.
- ↑ 2.0 2.1 "Anticonvulsants: Clinical". Wall & Melzack's Textbook of Pain (6 ed.). Elsevier Health Sciences. 2013. p. 508. ISBN 978-0-7020-4059-7. OCLC 1008841684. https://books.google.com/books?id=bNlvQJSqrB8C&q=XEN402.
- ↑ 3.0 3.1 "TV-45070: A Small Molecule for the Treatment of the Orphan Disease EM and Other Pain Disorders". Xenon Pharma. http://www.xenon-pharma.com/product-candidates/pain/pain-teva/.
- ↑ 4.0 4.1 "Teva and Xenon Announce Teva's World Wide License of Xenon's Pain Drug XEN402". Xenon Pharma. 11 December 2012. http://www.xenon-pharma.com/2012/12/teva-and-xenon/.
External links
- "Funapide - Flexion Therapeutics". AdisInsight. Springer Nature Switzerland AG. http://adisinsight.springer.com/drugs/800025125.
 |  |
